Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells

Gene Therapy

Volumn 22, Issue 1, 2015, Pages 76-86

  Bergamaschi, C ^a   Kulkarni, V ^a   Rosati, M ^a   Alicea, C ^a   Jalah, R ^a   Chen, S ^a   Bear, J ^a   Sardesai, N Y ^b   Valentin, A ^a   Felber, B K ^a   Pavlakis, G N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Inovio Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; IL15 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA VECTOR; EFFECTOR CELL; ELECTROPORATION; GENE TARGETING; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; RHESUS MONKEY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; PHYSIOLOGY;

MACACA; MACACA MULATTA;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPORATION; GENE EXPRESSION; GENETIC THERAPY; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-15; KILLER CELLS, NATURAL; MACACA MULATTA; T-LYMPHOCYTES; TRANSFECTION;

EID: 84920532579     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.84     Document Type: Article

References (63)

1. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395-1403.
2. Ma A, Koka RBurkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-679.
3. Steel JC, Waldmann TAMorris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41.
4. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002; 195: 1523-1532.
5. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8: 591-599.
6. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004; 200: 825-834.
7. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP et al. Interleukin (IL)-15R [alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med 2003; 197: 977-984.
8. Sandau MM, Schluns KS, Lefrancois L, Jameson SC. Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol 2004; 173: 6537-6541.
9. Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang GM, Alicea C et al. Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J Immunol 2009; 183: 3064-3072.
10. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008; 283: 4189-4199.
11. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205: 1213-1225.
12. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17: 537-547.
13. Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15. IL-15Ralpha cytokine compared to IL-15 monomer. J Biol Chem 2013; 288: 18093-18103.
14. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 2012; 120: e1-e8.
15. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008; 180: 2099-2106.
16. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD et al. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc Natl Acad Sci USA 2006; 103: 9166-9171.
17. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-6080.
18. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. Gene Therapy 2014; 21: 393-401.
19. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417-2426.
20. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011; 117: 4787-4795.
21. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-484.
22. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735-1742.
23. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6: 1678-1692.
24. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53: 296-302.
25. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008; 9: 776-788.
26. Felber BK, Valentin A, Rosati M, Bergamaschi C, Pavlakis GN. HIV DNA Vaccine: Stepwise improvements make a difference. Vaccines 2014; 2: 354-379.
27. Jalah R, Rosati M, Kulkarni V, Patel V, Bergamaschi C, Valentin A et al. Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol 2007; 26: 827-840.
28. Hutnick NA, Myles DJ, Ferraro B, Lucke C, Lin F, Yan J et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 2012; 23: 943-950.
29. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011; 23: 421-429.
30. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013; 4: 354.
31. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci USA 2013; 110: 2975-2980.
32. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci USA 2009; 106: 15831-15836.
33. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008; 26: 5223-5229.
34. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26: 3112-3120.
35. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83: 4624-4630.
36. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7: e29231.
37. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208: 818-829.
38. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6: e19252.
39. Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 21: 629-643.
40. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother 2012; 8: 1620-1629.
41. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
42. Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010; 28: 1962-1974.
43. Ugen KE, Kutzler MA, Marrero B, Westover J, Coppola D, Weiner DB et al. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 2006; 13: 969-974.
44. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-5903.
45. Hartikka J, Sukhu L, Buchner C, Hazard D, Bozoukova V, Margalith M et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4: 407-415.
46. Lugli E, Mueller YM, Lewis MG, Villinger F, Katsikis PD, Roederer M. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood 2011; 118: 2520-2529.
47. Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood 2011; 118: 6845-6848.
48. Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S et al. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology 2005; 116: 354-361.
49. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17: 1290-1297.
50. Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 2013; 8: 33-42.
51. Picker LJ, Reed-Inderbitzin EF, Hagen SI, Edgar JB, Hansen SG, Legasse A et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 2006; 116: 1514-1524.
52. Berger C, Berger M, Beard BC, Kiem HP, Gooley TA, Riddell SR. Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. PLoS One 2013; 8: e56268.
53. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, Yovandich JL et al. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 2010; 116: 3238-3248.
54. Mueller YM, Petrovas C, Bojczuk PM, Dimitriou ID, Beer B, Silvera P et al. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J Virol 2005; 79: 4877-4885.
55. Imamichi H, Sereti I, Lane HC. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur J Immunol 2008; 38: 1621-1630.
56. Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 2008; 84: 973-980.
57. Pistilli EE, Quinn LS. From anabolic to oxidative: reconsidering the roles of IL-15 and IL-15Ralpha in skeletal muscle. Exerc Sport Sci Rev 2013; 41: 100-106.
58. Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano YWest SM et al. Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol 2007; 178: 3492-3504.
59. Mueller YM, Do DH, Altork SR, Artlett CM, Gracely EJ, Katsetos CD et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol 2008; 180: 350-360.
60. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68: 2972-2983.
61. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013; 73: 3075-3086.
62. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13: 1551-1559.
63. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.